Novartis

Novartis Paid $400,000 to Trump's Atty Michael Cohen According to Stormy Daniels' Lawyer
Novartis
Flag link:
Aurobindo bids $1.6B for Novartis' U.S. dermatology generics: report
Aurobindo bids $1.6B for Novartis' U.S. dermatology generics: report
Fierce Pharma
Aurobindo
Novartis
Sandoz
M&A
dermatology
India
Flag link:
FDA approves Novartis combo therapy for aggressive type of thyroid cancer
FDA approves Novartis combo therapy for aggressive type of thyroid cancer
Reuters
Novartis
FDA
Tafinlar
Mekinist
anaplastic thyroid cancer
Flag link:
New approval sets up CAR-T showdown for Gilead, Novartis
New approval sets up CAR-T showdown for Gilead, Novartis
Biopharma Dive
Kymriah
Novartis
cell therapy
Yescarta
Gilead Sciences
Flag link:
Eyeing Eylea’s $5B sales, Novartis touts solid 12-week dosing data for its rival RTH258
Eyeing Eylea’s $5B sales, Novartis touts solid 12-week dosing data for its rival RTH258
Endpoints
Novartis
Regeneron
Eylea
RTH258
wet age-related macular degeneration
Flag link:
4 Huge Pharma Deals in 4 Months Is Just the Beginning
4 Huge Pharma Deals in 4 Months Is Just the Beginning
Motley Fool
M&A
Takeda
Shire
Novartis
AveXis
Sanofi
Bioverativ
Celgene
Juno Therapeutics
Flag link:
First Patient Dosed in Avexis' Phase 3 Trial of AVXS-101 in Pre-Symptomatic Spinal Muscular Atrophy
First Patient Dosed in Avexis' Phase 3 Trial of AVXS-101 in Pre-Symptomatic Spinal Muscular Atrophy
CP Wire
AveXis
Novartis
M&A
clinical trials
AVXS-101
gene therapy
spinal muscular atrophy
Flag link:
Novartis CEO Vas Narasimhan is raising the bar on second-gen cancer drug studies
Novartis CEO Vas Narasimhan is raising the bar on second-gen cancer drug studies
Endpoints
Novartis
cancer
Pharma CEOs
Vas Narasimhan
Flag link:
Novartis pads case for new MS blockbuster with disease-progression analysis
Novartis pads case for new MS blockbuster with disease-progression analysis
Fierce Pharma
Novartis
MS
multiple sclerois
siponimod
Flag link:
Good news, Glaxo: Novartis' Advair copy definitely won't see the market this year
Good news, Glaxo: Novartis' Advair copy definitely won't see the market this year
Fierce Pharma
Novartis
GSK
Advair
asthma
Flag link:
[video]Did Novartis Overpay for AveXis?
[video]Did Novartis Overpay for AveXis?
Motley Fool
Novartis
AveXis
gene therapy
M&A
Flag link:
Q1 kicks off with J&J, Novartis, Glaxo results
Q1 kicks off with J&J, Novartis, Glaxo results
Biopharma Dive
earnings
JNJ
Novartis
GSK
Flag link:
3 Biotech Stocks That Soared This Week
3 Biotech Stocks That Soared This Week
Motley Fool
AveXis
Abeona Therapeutics
Spectrum Pharmaceuticals
Novartis
M&A
poziotinib
EB-101
Flag link:
Novartis CEO: How To Create Cheaper Alternatives To The Most Expensive Drugs
Novartis CEO: How To Create Cheaper Alternatives To The Most Expensive Drugs
Forbes
Novartis
Pharma CEOs
FDA
drug pricing
Vasant Narasimham
Flag link:
Novartis offloads failed cancer drug to Oncology Venture
Novartis offloads failed cancer drug to Oncology Venture
Fierce Biotech
Novartis
Oncology Venture
dovitinib
kidney cancer
cancer
Flag link:
Physician payments linked to scripts for cancer drugs from Novartis, Pfizer and more: study
Physician payments linked to scripts for cancer drugs from Novartis, Pfizer and more: study
Fierce Pharma
physician payments
Novartis
Pfizer
Bayer
Bristol-Myers Squibb
cancer
Flag link:
Why Did Novartis Spend $9 Billion On Gene Therapy? CEO Says: 'A Journey To Focus On Data And Digital'
Why Did Novartis Spend $9 Billion On Gene Therapy? CEO Says: 'A Journey To Focus On Data And Digital'
Forbes
Novartis
Vas Narasimhan
M&A
gene therapy
AveXis
Flag link:
Biogen faces increased 'pressure' after AveXis buyout by Novartis
Biogen faces increased 'pressure' after AveXis buyout by Novartis
Marketwatch
Novartis
AveXis
Biogen
SMA
M&A
AVXS-1-1
Spinraza
Flag link:
Novartis buying AveXis for $8.7 billion to strengthen gene therapy capabilities
Novartis buying AveXis for $8.7 billion to strengthen gene therapy capabilities
Stat
Novartis
M&A
AveXis
gene therapy
AVXS-101
SMA
spinal muscular atrophy
Flag link:
Novartis, still embroiled in Greek probe, faces kickback allegation in China—again
Novartis, still embroiled in Greek probe, faces kickback allegation in China—again
Fierce Pharma
Novartis
China
Greece
kickbacks
bribery
Flag link:

Pages